SCHEDULE: JPMorgan Chase Discloses 4.0% Stake in Bristol-Myers Squibb

JPMorgan Chase & Co. has reported a 4.0% beneficial ownership stake in Bristol-Myers Squibb Company, totaling over 81 million shares, as detailed in its latest Schedule 13G filing.

Summary

• JPMorgan Chase & Co. has filed an Amendment No. 1 to Schedule 13G, disclosing its beneficial ownership in Bristol-Myers Squibb Company.
• The filing indicates JPMorgan Chase & Co. beneficially owns 81,890,781 shares of Bristol-Myers Squibb's Common Stock, $0.10 Par Value.
• This aggregate amount represents 4.0% of the class of securities.
• JPMorgan Chase & Co. holds sole voting power over 71,741,508 shares and shared voting power over 790,804 shares.
• The institution also holds sole dispositive power over 81,264,020 shares and shared dispositive power over 625,305 shares.
• JPMorgan Chase & Co. is classified as a parent holding company or control person.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• A significant institutional investment by JPMorgan Chase & Co. may signal confidence in Bristol-Myers Squibb's long-term prospects.
• The filing confirms the investment is for ordinary course of business, indicating a passive, non-activist stake.

Future Outlook

The filing does not provide any forward-looking statements or guidance from Bristol-Myers Squibb Company. JPMorgan Chase & Co. states that its holdings are in the ordinary course of business and not for control purposes.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

Bristol-Myers Squibb is a global biopharmaceutical company. The disclosure of a significant stake by a major financial institution like JPMorgan Chase & Co. is a routine event in the context of large-cap public companies, reflecting institutional portfolio management and investment strategies within the healthcare sector.

Stakeholder Impact

• Shareholders of Bristol-Myers Squibb may view the continued significant stake by a major institutional investor like JPMorgan Chase & Co. as a sign of stability and institutional confidence in the company.

Key Dates

Keywords

Bristol-Myers Squibb, JPMorgan Chase, Schedule 13G, beneficial ownership, common stock, institutional investor, pharmaceutical, healthcare